Comparative Pharmacology
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus CLARINEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus CLARINEX.
BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE vs CLARINEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromodiphenhydramine hydrochloride is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms. Codeine phosphate is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects. Combination provides enhanced cough suppression.
Desloratadine is a long-acting tricyclic histamine antagonist with selective peripheral H1-receptor antagonist activity. It inhibits histamine release from mast cells and reduces allergic inflammation.
5 mL of oral solution (containing bromodiphenhydramine hydrochloride 12.5 mg and codeine phosphate 10 mg) every 4-6 hours as needed; maximum 4 doses in 24 hours.
5 mg orally once daily.
None Documented
None Documented
Codeine: 2.5-3.5 h (adults), prolonged in hepatic impairment. Diphenhydramine: 4-8 h (adults), extended in elderly.
Terminal elimination half-life is approximately 27 hours (range 20-30 hours). This long half-life supports once-daily dosing and allows for steady-state concentrations within 7 days.
Renal: 70-80% as metabolites (codeine ~10% unchanged; diphenhydramine <5% unchanged). Biliary/fecal: 20-30%.
Desloratadine is primarily eliminated via renal excretion (~40% as metabolites) and fecal elimination (~45% as metabolites). Less than 2% is excreted unchanged in urine.
Category A/B
Category C
Antihistamine
Antihistamine